Cortice Biosciences, Inc.
15
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
66.7%
10 terminated/withdrawn out of 15 trials
28.6%
-57.9% vs industry average
0%
0 trials in Phase 3/4
150%
6 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Role: collaborator
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Role: collaborator
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Role: collaborator
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Role: lead
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
Role: collaborator
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Role: collaborator
TPI 287 in Breast Cancer Metastatic to the Brain
Role: collaborator
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Role: lead
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
Role: collaborator
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
Role: collaborator
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
Role: lead
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Role: lead
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
Role: collaborator
Study of TPI 287 in Patients With Advanced Malignancies
Role: lead
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Role: lead
All 15 trials loaded